University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USA.
Ther Clin Risk Manag. 2011;7:265-73. doi: 10.2147/TCRM.S15544. Epub 2011 Jul 1.
Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.
最近，多种 C1 抑制剂（C1-INH）替代产品已被批准用于治疗遗传性血管水肿（HAE）。本综述总结了 HAE 及其当前的治疗方法，并重点介绍了新型 C1-INH 替代物——康替唑阿尔法的从实验室到临床的试验结果。康替唑阿尔法与其他 C1-INH 替代产品不同，因为它是从转基因兔子中生产的，而不是从人类血浆供体中提取的，这可以潜在地提供无限来源的药物，而不必担心传染性传播。迄今为止产生的临床试验数据表明，康替唑阿尔法治疗急性 HAE 发作是安全有效的。
Zotero 插件